Revista Brasileira de Hematologia e Hemoterapia
versión impresa ISSN 1516-8484
MAIOLINO, Angelo et al. Risk assessment for multiple myeloma: preliminary results of the brazilian myeloma study group. Rev. Bras. Hematol. Hemoter. [online]. 2008, vol.30, suppl.2, pp. 6-9. ISSN 1516-8484. http://dx.doi.org/10.1590/S1516-84842008000800004.
The Durie/Salmon staging system continues to be used worldwide in patients with multiple myeloma. However, in recent years, new systems have been proposed. The International Myeloma Working Group performed a retrospective study with 11,179 patients and proposed an "International Staging System" utilizing serum levels of â2 microglobulin and albumin. In addition, current research has focused on the usefulness of cytogenetic and molecular data as prognostic factors. These data suggest that these parameters are powerful discriminators of a poor prognostic group of myeloma patients. Indeed, these prognostic indexes have been utilized in clinical trials, with interesting and encouraging results.
Palabras llave : Prognostic factors; multiple myeloma; molecular biology; treatment.